TriSalus Life Sciences (TLSIW) Cost of Revenue (2022 - 2026)

TriSalus Life Sciences has reported Cost of Revenue for 5 years, with the latest figure at $7.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 395.85% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at $12.9 million (down 16.95% YoY), and the FY2025 full-year result was $7.0 million, down 73.04% from the prior year.
• Cost of Revenue for Q1 2026 stood at $7.4 million, up from $1.8 million in the prior quarter.
• The five-year high for Cost of Revenue was $7.4 million in Q1 2026, with the low at -$6.6 million in Q4 2022.
• Historically, Cost of Revenue has averaged $1.9 million across 5 years, with a median of $1.5 million in 2025.
• Annual changes were most pronounced in 2023 — Cost of Revenue plunged 80.56% — and 2024, when it surged 1104.47%.
• TriSalus Life Sciences' Cost of Revenue stood at -$6.6 million in 2022, then soared by 108.79% to $582000.0 in 2023, then surged by 1104.47% to $7.0 million in 2024, then slumped by 74.86% to $1.8 million in 2025, then surged by 320.72% to $7.4 million in 2026.
• The last three Cost of Revenue figures came in at $7.4 million (Q1 2026), $1.8 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.